Literature DB >> 15968727

Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.

Li-Ning Xu1, Sheng-Quan Zou, Jian-Ming Wang.   

Abstract

AIM: To study the role of Fas and Fas ligand (FasL) in biological behaviors of gallbladder carcinoma, and their correlated action and mechanism in tumor escape.
METHODS: Streptavidin-biotin-peroxidase immunohistochemistry technique was used to study the expression of Fas and FasL protein in 26 gallbladder carcinoma tissues, 18 gallbladder adenoma tissues, 3 gallbladder dysplasia tissues and 20 chronic cholecystitis tissues. Apoptosis of the infiltrating lymphocytes in these tissues was studied by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) method. Expression of both proteins and apoptosis of the tumor infiltrating lymphocytes in cancer tissues of primary foci was compared with clinicopathological features of gallbladder carcinoma.
RESULTS: The positive rates of Fas were not significantly different among carcinoma, adenoma, dysplasia and chronic cholecystitis. The positive rate of FasL in carcinoma was significantly higher than that in chronic cholecystitis (chi(2) = 4.89, P<0.05). The apoptotic index (AI) in carcinoma was significantly higher than that in adenoma (t' = 4.19, P<0.01) and chronic cholecystitis (t' = 8.06, P<0.01). The AI was significantly lower in well-differentiated carcinoma and Nevin I-III carcinoma than that in poorly-differentiated carcinoma (t' = 2.63, P<0.05) and Nevin IV-V carcinoma (t' = 3.33, P<0.01). The confidence interval (CI) of infiltrating lymphocytes in adenoma, chronic cholecystitis, well-differentiated carcinoma and Nevin I-III carcinoma was very significantly lower than that in carcinoma (t' = 6.99, P<0.01), adenoma (t' = 3.66, P<0.01), poorly-differentiated carcinoma (t' = 5.31, P<0.01) and Nevin IV-V carcinoma (t' = 3.76, P<0.01), respectively. The CI of apoptosis of infiltrating lymphocytes in well-differentiated carcinoma was significantly lower than that in poorly-differentiated carcinoma (t = 2.52, P<0.05), and was not significantly lower in Nevin I-III carcinoma than in Nevin IV-V carcinoma (t = 1.42, P>0.05). Apoptosis of infiltrating lymphocytes was not discovered in adenoma and chronic cholecystitis.
CONCLUSION: FasL expressed in gallbladder carcinoma cells permits tumor cells to escape from immune surveillance of organism by inducing apoptosis in infiltrating lymphocytes of carcinoma tissues. Up-regulation of FasL expression plays an important role in invasive depth, histological classification and metastasis of gallbladder carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968727      PMCID: PMC4316023          DOI: 10.3748/wjg.v11.i24.3719

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

Review 2.  Carcinoma of the gallbladder.

Authors:  Sanjeev Misra; Arun Chaturvedi; Naresh C Misra; Indra D Sharma
Journal:  Lancet Oncol       Date:  2003-03       Impact factor: 41.316

3.  Impact of human bladder cancer cell architecture on autologous T-lymphocyte activation.

Authors:  Virginie Dangles; Pierre Validire; Mireille Wertheimer; Sophie Richon; Christophe Bovin; Dominique Zeliszewski; Guy Vallancien; Dominique Bellet
Journal:  Int J Cancer       Date:  2002-03-01       Impact factor: 7.396

4.  Apoptotic depletion of infiltrating mucosal lymphocytes associated with Fas ligand expression by Helicobacter pylori-infected gastric mucosal epithelium: human glandular stomach as a site of immune privilege.

Authors:  S Koyama
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

5.  Cytochrome P-450 expression and lipid peroxidation in gallbladder cancer.

Authors:  Manoj Pandey; Lal B Sharma; Vijay K Shukla
Journal:  J Surg Oncol       Date:  2003-03       Impact factor: 3.454

6.  Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.

Authors:  Isabelle Viard-Leveugle; Sylvie Veyrenc; Lars E French; Christian Brambilla; Elisabeth Brambilla
Journal:  J Pathol       Date:  2003-10       Impact factor: 7.996

7.  Gallbladder cancer in northern Jordan.

Authors:  Kamal E Bani-Hani; Rami J Yaghan; Ismail I Matalka; Nawaf J Shatnawi
Journal:  J Gastroenterol Hepatol       Date:  2003-08       Impact factor: 4.029

8.  Gallbladder cancer: an 'Indian' disease.

Authors:  V K Kapoor; A J McMichael
Journal:  Natl Med J India       Date:  2003 Jul-Aug       Impact factor: 0.537

9.  Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation.

Authors:  M Weller; U Malipiero; A Aguzzi; J C Reed; A Fontana
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

10.  Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression.

Authors:  A Houston; M W Bennett; G C O'Sullivan; F Shanahan; J O'Connell
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more
  3 in total

1.  Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues.

Authors:  Qian Li; Jie Peng; Xin-Hua Li; Ting Liu; Qing-Chun Liang; Gui-Ying Zhang
Journal:  World J Gastroenterol       Date:  2010-03-14       Impact factor: 5.742

2.  Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues.

Authors:  Yin Li; Da-Fu Xu; Dong Jiang; Jun Zhao; Jin-Feng Ge; Shi-Ying Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

3.  Death receptor (DR4) haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian population.

Authors:  Rajani Rai; Kiran L Sharma; Surbhi Sharma; Sanjeev Misra; Ashok Kumar; Balraj Mittal
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.